

Author Index-1998

- Abrahamson, M. 116(ab)
Ackermann, RJ. 121(ab)
Adams, EJ. 278
Adamski, K. 116(ab)
Afriyie, MO. 126(ab)
Ågren, BN. 196
Ahlberg, AW. 116(ab), 186
Aita, JF. 113(ab)
Akamune, A. 125(ab), 191
Al-Bunny, A. 269
Alledina, Y. 116(ab)
Al-Mohannadi, S. 269
Alonso, JC. 132(ab)
Alonso, O. 119(ab)
Al-Za'abi, K. 269
Andrews, D. 119(ab)
Aoki, T. 30
Ardeel, HC. 134(ab)
Ariola-Pienschke, E. 245
Arroyo, A. 124(ab)
Atkins, HL. 80
Audenaert, K. 130(ab)
- Babich, JW. 113(ab)
Bacher, J. 130(ab)
Backstrom, P. 133(ab)
Baker, MK. 120(ab)
Baldwin, P. 130(ab)
Barrow, SA. 113(ab), 114(ab), 117(ab)
Bechtel, G. 235
Bender, H. 129(ab)
Bertoldo, A. 130(ab)
Beyer, T. 128(ab)
Biersack, H-J. 129(ab)
Bin, L. 123(ab)
Blais, M. 206
Boccagna, F. 128(ab)
Bogsrud, TV. 124(ab)
Bohdiewicz, PJ. 155
Bonab, AA. 113(ab)
Brown, K. 87
Bruch, PM. 113(ab)
Busch, A. 116(ab)
Buscombe, JR. 127(ab)
Buse, M. 129(ab)
Bybel, B. 206
- Cacciabauda, J. 115(ab)
Caldwell, CB. 100
Cao, Z. 178
Carey, J. 121(ab)
Carlson, C. 43
Carlson, KA. 133(ab), 135(ab), 136(ab)
Carson, R. 130(ab)
Casati, R. 128(ab)
Casey, D. 32
Castramayor, EM. 133(ab)
Chandler, LD. 124(ab)
Chang, CW. 125(ab)
Chen, HR. 132(ab)
Chen, JB. 125(ab)
Chen, KG. 126(ab)
- Chen, M-N. 124(ab), 125(ab), 130(ab)
Chin, BB. 117(ab)
Chou, KL. 132(ab)
Civelek, AC. 117(ab)
Clapp, DA. 115(ab)
Clarke, GH. 257
Căncă, J. 119(ab)
Cobelli, C. 130(ab)
Code, C. 17
Coleman, RE. 127(ab)
Collins, AM. 115(ab)
Colombo, FR. 128(ab)
Conway, AA. 114(ab)
Cook, TE. 134(ab)
Cowell, SF. 17, 278
Crawford, ES. 38
Cronin, VR. 213
Cross, DM. 115(ab), 186, 265
Cuadra, JI. 132(ab)
Cuklanz, EJ. 57, 210
Czerniecki, B. 120(ab)
- D'Asseler, Y. 130(ab)
Dachille, MA. 128(ab)
Dado, A. 127(ab)
Daley, LJ. 118(ab)
Dalipaj, MM. 133(ab), 134(ab)
Danielsson, M. 120(ab)
Daube-Witherspoon, ME. 130(ab)
Davidhizar, R. 235
Day, PJ. 121(ab)
DeMan, P. 122(ab)
den Hollander, W. 127(ab)
Denhartog, P. 23
Der, M. 130(ab)
Dey, HM. 118(ab)
Dierekx, R. 130(ab)
Diestelhorst, S. 134(ab)
Dillehay, GH. 115(ab)
Donat, J. 116(ab)
Dowd, SB. 235
Driedger, AA. 206
Duncan, BG. 120(ab)
Duncan, K. 228
Dunlop, D. 121(ab)
Dunn, RM. 121(ab)
Dunnwald, LK. 120(ab)
Durack, L. 128(ab)
- Eary, J. 128(ab)
Eary, JF. 120(ab)
Eijndhoven, J. 127(ab)
Elliott, DG. 123(ab)
Elliott, G. 130(ab)
Engelin, L. 127(ab)
Everaert, H. 4, 72, 164
Everett, J. 130(ab)
- Fain, R. 134(ab)
Fannin, BJ. 134(ab)
Ferency, S. 116(ab)
Ferg, M. 103
- Ferraro-Borgida, MJ. 115(ab)
Fischer, S. 116(ab)
Fischman, AJ. 113(ab), 114(ab), 117(ab)
Franken, PR. 4, 72, 164
Fry, J. 127(ab)
Fujioka, H. 125(ab), 191
Fujita, T. 123(ab)
- Gabrys, J. 116(ab)
Gebhard, MW. 122(ab)
Gering, MM. 115(ab)
Gibbons, RJ. 133(ab)
Gilbert, S. 1, 69, 153, 225
Goldenberg, DM. 121(ab)
Golder, K. 119(ab)
Goldsmith, SJ. 119(ab)
Golosovker, O. 119(ab)
Göransson, MB. 196
Gordon, BM. 129(ab)
Gordon, L. 129(ab)
Grant, S. 117(ab)
Gratzer, SE. 133(ab)
Green, J. 130(ab)
Green, S. 130(ab)
Greenley, W. 130(ab)
Griffith, S. 63
Grocc, KD. 135(ab)
Gross, K. 91
Guerra, P. 132(ab)
Guisoli, P. 119(ab)
Guy, R. 257
- Hachamovitch, R. 115(ab)
Haenchen, MG. 124(ab)
Hahn, K. 116(ab)
Halama, JR. 115(ab)
Halkar, R. 117(ab)
Hamblen, SM. 127(ab)
Hambye, A-S. 4, 72, 164
Hankins, JH. 113(ab)
Hartnett, SD. 120(ab)
Hatherly, R. 120(ab)
Hattori, N. 123(ab)
Haun, AS. 136(ab)
Heller, GV. 115(ab), 116(ab), 121(ab), 186, 265
Helsabeck, C. 120(ab)
Hendler, A. 116(ab)
Henkin, RE. 115(ab), 129(ab)
Herbst, J. 59, 219
Herold, TJ. 124(ab)
Herscovitch, P. 130(ab)
Hershkop, M. 116(ab)
Hewitt, T. 133(ab)
Hilson, AJW. 133(ab)
Hinkle, G. 127(ab)
Hinphy, P. 119(ab)
Hoh, CK. 43
Holder, LE. 120(ab), 174, 178
Homs, CJ. 124(ab)
- Hope, E. 43
Horn, D. 100
Horwitz, E. 224
Huang, DT. 118(ab), 121(ab), 130(ab), 135(ab)
Huang, WS. 126(ab)
Huh, SH. 124(ab)
Hung, JC. 118(ab), 121(ab), 124(ab), 125(ab), 130(ab), 133(ab), 134(ab)
Hutchins, GD. 134(ab)
- Ichise, M. 23, 114(ab)
Ikehira, H. 30
Ikezoe, J. 125(ab), 191
Inoue, T. 125(ab), 191
Intenzo, C. 119(ab)
Inubushi, M. 123(ab)
Irvine, P. 134(ab)
Ishimaru, Y. 125(ab), 191
Ito, H. 30
- Jacob, A. 269
Jacobs, GI. 130(ab)
Jacobsson, H. 120(ab)
Jahan, S. 269
Jansson, BA. 196
Jerin, J. 128(ab)
Jiang, N. 123(ab)
Johnson, R. 126(ab)
Johnston, RE. 94
Jonsson, C. 120(ab)
Jordan, C. 119(ab)
Juaneza, RJ. 135(ab)
Juweid, M. 121(ab)
- Kairemo, KJA. 118(ab)
Kanal, KM. 122(ab)
Kang, JT. 126(ab)
Karesh, SM. 115(ab)
Karonen, S-L. 118(ab)
Karp, JS. 118(ab)
Keim, LW. 113(ab)
Kelty, NL. 114(ab), 120(ab), 123(ab), 174
Khan, SH. 114(ab), 120(ab), 174
Kida, T. 128(ab)
Kilburn-Watt, E. 278
Kim, A. 32
Kim, S. 119(ab)
Klaus, DH. 117(ab)
Klein, EC. 128(ab)
Klit, L. 56
Knight, LC. 87
Koches, TS. 115(ab)
Komori, E. 123(ab)
Konishi, J. 123(ab)
Koole, M. 130(ab)
Kosegi, JE. 200
Kowalsky, RJ. 94
Kozar, JJ. 120(ab)
Krause, SJ. 135(ab)
Krevsky, B. 87
Kroger, K. 124(ab)
- Krzos, JR. 129(ab)
Kudoh, T. 123(ab)
Kwan, D. 23
- Lacy, JL. 121(ab)
Lahar, B. 91
Lahorte, P. 130(ab)
Larsson, SA. 120(ab)
Laymon, CM. 127(ab)
Leahey, D. 51, 52, 101, 209, 284
Lee, JM. 117(ab)
Lee, JS. 132(ab)
Lees, RS. 117(ab)
Lemahieu, I. 130(ab)
Leo, R. 128(ab)
Leong, LK. 119(ab)
Leveque, F. 126(ab)
Levine, MG. 116(ab)
Lewis, DH. 115(ab)
Liao, SQ. 126(ab)
Limouris, GS. 132(ab)
Lin, HM. 125(ab)
Lin, YD. 132(ab)
Linthicum, W. 130(ab), 130(ab)
Littlefield, JL. 124(ab)
Liu, HG. 114(ab)
Liu, P. 116(ab)
Liu, RS. 125(ab), 126(ab), 132(ab)
Lowinger, T. 124(ab)
Lu, JM. 126(ab)
Lu, X. 123(ab)
Luk, P. 128(ab)
- Macey, DJ. 123(ab)
Madras, BK. 113(ab)
Madsen, M. 133(ab)
Maes, A. 4, 72, 164
Magoun, S. 91
Mahone, TJ. 114(ab)
Mahoney, DW. 118(ab), 124(ab), 130(ab)
Mankoff, DA. 120(ab)
Mann, A. 186, 265
Marcus, CS. 134(ab)
Maruno, H. 252
Mas, JC. 26
Masuda, K. 128(ab)
Mathis, CA. 128(ab)
Matsuo, S. 128(ab)
Maurer, AH. 87
Mazzilli, TV. 124(ab)
McBride, JG. 124(ab)
McCool, D. 127(ab)
McEnerney, K. 43
McGill, CC. 115(ab), 121(ab)
McGough, CG. 121(ab)
McKay, WJ. 257
McKee, BT. 133(ab)
Meli, SM. 123(ab)
Meltzer, CC. 128(ab)
Meredit, RF. 123(ab)
Mesotten, L. 4, 72, 164
Milko, DL. 128(ab)

- Mishkin, F, 126(ab), 134(ab)
Mizuno, S, 30
Molino, C, 132(ab)
Morita, R, 128(ab)
Morris, RS, 186
Mortelmans, L, 4, 72, 164
Mosman, EA, 133(ab)
Motee, HP, 133(ab)
Mountz, JM, 114(ab)
Moyna, NM, 116(ab)
Murase, K, 125(ab), 191
Murata, H, 252
Murphy, P, 116(ab)
Mussivand, TV, 133(ab)
Mut, F, 119(ab)
- Natale, D, 122(ab)
Neagley, FL, 208
Nelson, R, 133(ab)
Ng, CK, 118(ab)
Nguyen, T, 134(ab)
Nichols, D, 59, 103, 223
Nicodemus, CF, 117(ab)
Nikula, TK, 118(ab)
Nitke, SJ, 129(ab)
Noma, K, 128(ab)
Núñez, M, 119(ab), 133(ab)
Nyak, N, 121(ab)
- O'Connor, MK, 119(ab), 122(ab)
Ohnishi, H, 128(ab)
Olsen, J, 127(ab)
Onoguchi, M, 252
Osei-Boah, P, 126(ab)
Owunwanne, A, 269
- Packard, AB, 121(ab)
Pagani, M, 120(ab)
Palestro, CJ, 126(ab)
Parekh, JS, 132(ab)
- Parkinson, DE, 128(ab)
Patel, J, 119(ab)
Patel, M, 269
Patel, Y, 124(ab)
Patterson, H, 257
Pena, O, 134(ab)
Peterson, LJ, 133(ab)
Pham, HL, 126(ab), 134(ab)
Pham, PK, 120(ab)
Phillips, JM, 115(ab), 116(ab)
Phillips, V, 127(ab)
Pickett, MW, 200
Piriz, J, 186
Ponath, C, 129(ab)
Ponto, JA, 99, 262, 283
Pozderac, R, 127(ab)
Prekeges, J, 50
Prussin, SG, 32
Puckett, CL, 132(ab)
Purnell, SD, 124(ab)
- Quinton, T, 274
- Ratica, DM, 128(ab)
Reinhardt, M, 117(ab)
Revesz, G, 87
Reynolds, C, 120(ab)
Riggin, SL, 118(ab)
Rini, J, 119(ab)
Roßmüller, B, 116(ab)
Rose Wolf, GE, 248
Rosenbaum, D, 116(ab)
Rosner, N, 117(ab)
Rossman, PJ, 122(ab)
Rothfusz, B, 117(ab)
Roy, L, 154, 227
Rubin, RH, 114(ab)
Rubio, C, 132(ab)
Ruddy, TD, 133(ab), 134(ab)
- Russell, A, 115(ab), 116(ab)
Ruszkiewicz, JA, 128(ab)
- Sa'ad, M, 269
Sajdak, R, 245
San Pedro, EC, 114(ab)
Saver, A, 120(ab)
Schauwecker, DS, 134(ab)
Scheff, AM, 120(ab)
Schmit, CL, 134(ab)
Sdraiati, C, 128(ab)
Seo, IS, 124(ab)
Sestrich, S, 130(ab)
Seyer, MY, 135(ab)
Shalberg, PA, 113(ab)
Shapiro, B, 121(ab)
Sharkey, RM, 121(ab)
Sharpe, WD, 115(ab)
Shaw, D, 116(ab)
Shaw, SM, 274
Shih, W-J, 91
Shirakawa, S, 123(ab)
Shukla, SK, 132(ab)
Sileika, OA, 134(ab)
Sisson, JC, 121(ab)
Smallwood, J, 117(ab)
Smith, BM, 115(ab)
Smith, EM, 9
Smith, KF, 124(ab)
Smith, LG, 128(ab)
Smith, RJ, 118(ab)
Snowdon, GM, 204
Solmka, P, 133(ab)
Soriano, A, 132(ab)
Spaulding, SA, 121(ab)
Spetman, TA, 113(ab)
Spicer, KM, 129(ab)
Spies, SM, 125(ab)
Spies, WG, 125(ab)
Srivastava, SC, 80
- Stavraka, A, 132(ab)
Steves, AM, 38
Stipp, V, 91
Strömberg, S, 118(ab)
Sy, WM, 124(ab)
Sze, PC, 124(ab)
Szulc, M, 115(ab)
- Tadamura, E, 123(ab)
Takada, M, 128(ab)
Takamiya, Y, 117(ab)
Takano, H, 30
Takayama, T, 252
Tamaki, N, 123(ab)
Tanaka, F, 114(ab)
Taylor, A, 117(ab)
Taylor, RE, 123(ab)
Teates, TD, 132(ab)
Thakrar, DS, 127(ab)
Theofanous, G, 32
Thomas, C, 126(ab)
Thomas, KS, 3, 70, 200
Thomas, M, 130(ab)
Timpe, JT, 125(ab)
Tomas, B, 126(ab)
Townsend, DW, 128(ab)
Triantafyllou, N, 132(ab)
Tuli, M, 269
Turkington, TG, 127(ab)
- Urbain, JL, 87
- Valdivia, V, 126(ab)
Van den Maegdenbergh, V, 4
van Lingen, A, 127(ab)
Vandenbergh, S, 130(ab)
Vandevivere, J, 72
Vandierendonck, R, 206
Verma, AK, 124(ab)
- Vines, D, 23, 114(ab)
Vlahos, L, 132(ab)
Voliotopoulos, V, 132(ab)
- Wackers, FJT, 122(ab)
Wagner, JD, 134(ab)
Wagner, RH, 129(ab)
Wagner, RW, 115(ab)
Wahl, RL, 121(ab)
Wang, A, 118(ab), 133(ab)
Wang, HE, 125(ab)
Waterstram-Rich, KM, 200
Wells, P, 52
White, MP, 115(ab), 116(ab), 121(ab), 186, 265
Willi, S, 129(ab)
Williams, DA, 43
Winkle, WL, 134(ab), 135(ab)
Wirrell, J, 50
Wiseman, GA, 119(ab)
Wolf, GER, 248
- Yaakob, W, 129(ab)
Yamamoto, I, 128(ab)
Yamamoto, Y, 30, 191
Yang, CS, 126(ab)
Yeh, MY, 126(ab)
Yester, MV, 114(ab)
Yoshimura, M, 128(ab)
Yost, RW, 124(ab)
Yu, M-D, 274
Yu, MH, 126(ab)
- Zanzonico, P, 119(ab)
Zarca, M, 132(ab)
Zhang, J, 119(ab)
Zimmer, AM, 125(ab)

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION

(REQUIRED BY 39 U.S.C. 3685)

1. A. Title of Publication: The Journal of Nuclear Medicine Technology.
B. Publication Number: 966500.
2. Date of filing: September 29, 1998.
3. Frequency of issue: Quarterly.
3. A. Number of issues published annually: Four.
B. Annual Subscription price: \$70 in U.S.A.; \$75 in Canada and Pan-American countries; \$80 elsewhere.
4. Complete mailing address of known office of publication: 1850 Samuel Morse Dr., Reston, VA 20190-5316.
5. Complete mailing address of the headquarters of general business offices of the publisher: 1850 Samuel Morse Dr., Reston, VA 20190-5316.
6. Full names and complete mailing address of publisher, editor, and managing editor: Publisher: Society of Nuclear Medicine, Inc., 1850 Samuel Morse Dr., Reston, VA 20190-5316; Editor: Susan Gilbert, 1850 Samuel Morse Dr., Reston, VA 20190-5316; Managing Editor: Dawn Murphy, 1850 Samuel Morse Dr., Reston, VA 20190-5316.
7. Owner: Society of Nuclear Medicine, Inc., 1850 Samuel Morse Dr. Reston, VA 20190-5316.
8. Known bondholders, mortgages and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages or other securities: None. Society of Nuclear Medicine, Inc., is a nonprofit corporation; there are no shareholders.
9. The purpose, function and nonprofit status of this organization and the exempt status for federal income tax purposes have not changed during the preceding 12 months.
10. Extent and nature of circulation: (A) Total number of copies printed; average during preceding 12 months—7,979; actual copies printed in September 1998—8,574; (B) 1. Paid circulation: Sales through dealers and carriers, street vendors and counter sales—none. Actual copies in September 1998—none. 2. Mail subscriptions: average—7,226; actual copies in September 1998—7,642; (C) Total paid circulation: average—7,226; actual copies in September 1998—7,642; (D) Free distribution by mail, carrier or other means: samples, complimentary, and other free copies; average—21; actual copies in September 1998—19 (E) Free distribution outside the mail, carriers or other means: average—none; actual copies in September 1998—none; (F) Total free distribution: average—21; actual copies in September 1998—19; (G) Total distribution: average—7,247; actual copies in September 1998—7,661; (H) 1. Copies not distributed; office use, left over, unaccounted for, spoiled after printing; average—732; actual copies in September 1998—913. Returns from news agents—none. (I) Total: average—7,979; actual copies in September 1998—8,574.
11. I certify that the statements made by me are correct and complete; (signed) John S. Childs, Managing Director of Communications.

A

- Absorption**, ^{99m}Tc radiopharmaceuticals, onto disposable plastic syringes, 196
- ACNP News**, 63, 224
- Adsorption**, ^{99m}Tc radiopharmaceuticals, onto disposable plastic syringes, 196
- AECB**, see Atomic Energy Control Board
- Anatomy and physiology**, heart, nuclear cardiology, 4
- Anesthesia**, procedures to image nonhuman primates, nuclear medicine technologists, 128(ab)
- Animals**, procedures to image nonhuman primates, nuclear medicine technologists, 128(ab)
- Arterial sampling**, indwelling ports, quantitative PET studies, 130(ab)
- Artifacts**
 motion, head movement in simulated brain imaging, 257
 simulated frame-loss, myocardial perfusion imaging, 248
- Atomic Energy Control Board (AECB)**, recent decisions, 64
- Atria**, innervation, ^{11}C HED
 normal and stellectomy canine hearts, 134(ab)
 normal canine hearts, 134(ab)
- Attenuation compensation**, Chang algorithm on quantitative SPECT results, 178
- Attenuation correction**
 absolute quantitation, ^{131}I uptake, 123(ab)
 arm position effects, ^{99m}Tc sestamibi cardiac SPECT, 116(ab)
 artificial heart materials, 133(ab)
 inferior wall myocardial perfusion defects, prone imaging, 115(ab)
 practical considerations, fully corrected whole-body PET studies, 118(ab)
 radiopharmaceuticals in PET imaging, 228
 uniform, ^{111}In and ^{67}Ga SPECT, 117(ab)
- Author guidelines**, 288

B

- Blood activity**, measurement of, scintillation camera feasibility in, 125(ab)
- Bloodborne pathogens**, blood contamination of lead unit dose containers, commercially prepared doses, 200
- Blood-pool imaging**, agents for, cardiac function, 72
- Blood radioactivity**, measurement, for quantification of cerebral blood flow, gamma camera use in, 191
- Body outline**, serious artifacts due to, attenuation correction rCBF SPECT exams, 120(ab)
- Bone**, scintigraphy, osteoarthritis, 133(ab)
- Bone malignancy**, radionuclide therapy of, 80
- Bone scan**, wrist pathology, image fusion, 124(ab)
- Bone scintigraphy**, tibial metastases, from bronchogenic adenocarcinoma, 91

Book reviews

- Nuclear Medicine Procedure Manual 1997-98*, 50
- Radiopharmacy Computer Assisted Instruction for Medical Imaging Sciences*, 50

Brain

- ictal SPECT, technical protocol, 116(ab)
- imaging, simulated, head movement in, 257
- quantitative ^{99m}Tc BICISATE imaging, head injury patients, 113(ab)

Breast cancer

- imaging, prone scintimammography SPECT, 127(ab)
- sentinel node assessment in, lymphoscintigraphy, 120(ab)
- sentinel node localization in, ^{99m}Tc human serum albumin or sulfur colloid, 120(ab)
- ^{89}Sr therapy, 117(ab)

Bronchogenic adenocarcinoma

- tibial metastases in, 91

C

- Cancer**, bone malignancy, radiopharmaceuticals for therapy, 80
- Capsules**, compounded, ^{131}I , solution volume and storage time effects on dissolution, 274
- Carbon-11 HED**, atrial innervation
 normal and stellectomy canine hearts, 134(ab)
 normal canine hearts, 134(ab)
- Carotid artery**, thrombi, imaging with ^{99m}Tc labeled synthetic peptide, 117(ab)
- Cerebral blood flow**
 quantification of, blood radioactivity measurement with gamma camera, 191
 quantitative, ^{133}Xe and dynamic SPECT, 126(ab)
 regional, attenuation correction examinations, serious artifacts in, 120(ab)
- Chemotherapy**, ^{99m}Tc red blood cell labeling, adults and children, 265
- Chest pain**
 assessment, ^{99m}Tc -tetrofosmin liver clearance, 186
 during stress tests, reproducibility of ejection fraction measurements, 115(ab)
- Cholecystokinin**, response, spontaneous gallbladder contraction during cholescintigraphy, 124(ab)
- Cholescintigraphy**
 radionuclide hepatobiliary imaging, post-traumatic liver injuries, 123(ab)
 spontaneous gallbladder contraction during, CCK response and, 124(ab)
- Chromatography**, miniaturized, quality control procedures for radiopharmaceuticals, 125(ab)
- Cognition**, diagnosis, PET activation, 17
- Coincidence detection**, radiopharmaceuticals in PET imaging, 228

Coincidence imaging

- dual-head gamma camera, quality control of positron emitters on, 127(ab)
- FDG molecular and ^{99m}Tc tetrofosmin SPECT detection, viable myocardium, 115(ab)
- FDG SPECT, epilepsy, tumor, progressive aphasia and stroke, 114(ab)
- high-quality FDG studies, dual-headed gamma camera, 245

Contamination

- blood, lead unit dose containers, 200
- ^{99m}Tc -DTPA, in lung ventilation studies, 43

Copper filtration

- in dose calibration, measurement of ^{131}I and ^{111}In with, 94

Coronary artery disease

- ischemic, ^{99m}Tc -tetrofosmin liver clearance, 186
- nuclear cardiology in, 155

Cost-effectiveness

- whole-body FDG and off-site FDG PET, patient throughput for, 129(ab)

Critical thinking

- ACNP proficiency test, 38

Cross-calibration factor

- blood radioactivity measurement, with gamma camera, 191

D

- Dead-time measurements**, modern digital gamma camera systems, 119(ab)
- Dopamine transporters**
 imaging with ^{11}C β -CFT, lesioned rat, 135(ab)
 PET and SPECT imaging, altropane for, 113(ab)
- Dopascan**, ^{123}I β -CIT clinical evaluation, Parkinson's disease, 114(ab)
- Dose calibrator**
 copper filter, measurement of ^{131}I and ^{111}In with, 94
 geometry parameter for quality control, 127(ab)
- Dosimetry**, measurements, technical considerations of, 121(ab)

E

- ECAT ART scanner**, improved whole-body imaging, 128(ab)
- Editor's Page**
 future of *JNMT*, 1(ed)
 peer review process, 69(ed)
 SNM-TS membership, 153(ed)
 recognition of contributors, 225(ed)
- Ejection fraction**
 left ventricular, first-pass radionuclide angiography or gated blood-pool imaging, 134(ab)
 measurements, ^{99m}Tc -tetrofosmin, chest pain during stress tests, 115(ab)
- External radioactive reference markers**, SPECT, dopamine system, 114(ab)
- Extremity exposure**, ^{99m}Tc radiopharmaceutical preparation,

Filtered backprojection

dose from syringe procedures during, 32

F

Filtered backprojection, iterative reconstruction comparison, coincidence detection data, 118(ab)

Filtration problems, ^{111}In capromab pentetide, 283(le)

Fluorine-18-FDG

biodistribution patterns, plasma time-activity curve and external TLD measurement, 131(ab)
high-quality studies, dual-headed gamma camera, 245

molecular coincidence detection, ^{99m}Tc FDG tetrafosmin and, viable myocardium, 115(ab)

PET, lung cancer, Medicare coverage, 63

PET, spectral analysis approach for quantification, 130(ab)

6-Fluorine-18 FDOPA, robotic synthesis of, 125(ab)

Fluorodeoxyglucose, in PET imaging, 228

Fractionated kit, radiochemical purity, ^{99m}Tc -tetrafosmin, 128(ab)

Frame loss, simulated artifacts, myocardial perfusion imaging, 248

G

Gamma camera

dual-headed, high-quality FDG studies, 245

measurement of blood radioactivity, quantification of cerebral blood flow, 191

modern digital systems, dead-time measurements on, 119(ab)

static versus variable speed whole-body acquisition, organ uptake ratios, 126(ab)

system for wipe testing, 100(le)

Gastrointestinal bleeding

occult, imaged by ^{99m}Tc -HSA-D radionuclide angiography, 30

red cell labeling, in vitro versus in vivo, 87

Generator, ^{99m}Tc

elution time and eluate volume in, 118(ab)

fractionation elution performance, 130(ab)

Government Relations Office

annual report, 1997, 59

update, 103, 223

H

Head movement, simulated brain imaging, 257

Heart

anatomy and function, nuclear cardiology, 4, 72, 164

artificial, attenuation by materials, 133(ab)

Heat-damaged red blood cells, 204

Hepatobiliary imaging, radionuclide, post-traumatic liver injuries, 123(ab)

I

Image fusion technique, bimodality, CT, MR, SPECT and PET, 133(ab)

Image reconstruction

attenuation map effects, Chang algorithm, quantitative SPECT results, 178

iterative, filtered backprojection comparison, coincidence detection data, 118(ab)

PET, filtered backprojection versus expectation-maximization methods, 134(ab)

Image registration, anatomic localization of wrist pathology, 124(ab)

Imaging protocols, nuclear cardiology, evaluation of cardiac perfusion, 164

Immunoscintigraphy, melanectomized patients, 131(ab)

Index Medicus, 56(le)

Indium-111, measurement, dose calibrator assay with a copper filter, 94

Indium-111 capromab pentetide, monoclonal antibody imaging, prostate cancer, 174

preparation of, filtering, 283(le)

Indium-111 octreotide, imaging, meningioma and carcinoid tumor, 135(ab)

Indium-111 OncoScint[®], FDA approved, tumor imaging, 155

Indium-111 ProstaScint[®]

dual-isotope

decreased cost of, 129(ab)

prostate cancer, 174

protocol for, 120(ab)

Indium-111 satumomab pentetide

FDA approved, tumor imaging, 155

radiochemical purity of, quality control procedures, 125(ab)

Instrumentation, design and quality control, scintillation cameras, 9

Iodine-123

measurement, dose calibrator assay with a copper filter, 94

total-body scan, thyroid cancer and metastasis, 129(ab)

Iodine-123 IPPA, metabolic images, quantitative method for analysis, 133(ab)

Iodine-125, brachytherapy seeds, SPECT imaging of, 124(ab)

Iodine-131

high-dose therapy, radiation safety, 128(ab)

radiation safety, patient dies after therapy, 206

solution volume and storage time, effects on in vitro dissolution, 274

therapy

absolute quantitation of uptake, 123(ab)

thyroid stunning, 134(ab)

J

Joint Review Committee on Educational Programs in Nuclear Medicine Technology (JRCNMT), 57, 210

K

Kidney

determination of ERPF, ^{99m}Tc -MAG and single blood sampling, 23

shock wave lithotripsy trauma, ^{111}In platelets and ^{99m}Tc RBCs in imaging of, 136(ab)

L

Lead-glass syringe shields, ^{99m}Tc radiopharmaceutical preparation, dose from syringe procedures during, 32

Lead unit dose containers, single-use protective inserts, blood contamination and, 200

Lead-vial shields, ^{99m}Tc radiopharmaceutical preparation, dose from syringe procedures during, 32

Learning outcomes, assessment of, 278

Left ventricular ejection fraction, nuclear cardiology, 72

Left ventricular function, ^{191}mIr and ^{178}Ta comparison, first-pass radionuclide angiogram, 121(ab)

Lesion detection, assessment of, brain SPECT, 130(ab)

Lithotripsy, shock wave, trauma from, ^{111}In platelets and ^{99m}Tc RBCs in imaging of, 136(ab)

Liver, ^{99m}Tc -tetrafosmin clearance, acute chest pain patients, 186

Lung

quantitative imaging, for lung volume reduction surgery, 26

^{133}Xe ventilation, after perfusion imaging with ^{99m}Tc , 131(ab)

Lung cancer, bronchogenic adenocarcinoma, tibial metastases in, 91

Lung volume reduction surgery, lung scans in patient selection for, 26

Lymphoscintigraphy

breast cancer, sentinel node assessment in, 120(ab)

melanectomized patients, 131(ab)

M

Manpower data survey, Workforce Analysis Committee, 208

Medicare, coverage for ^{18}F -FDG PET in lung cancer, 63

Melanoma, immunoscintigraphy and lymphoscintigraphy indications in, 131(ab)

Meningioma

carcinoid tumor and, ^{111}In octreotide for imaging of, 135(ab)

surgery or radiation therapy, octreotide brain SPECT in, 119(ab)

Message from the President, 3, 70, 154, 227

Migrational anomalies, congenital thyroid, scintigraphy, 129(ab)

Monoclonal antibody

for tumor imaging, ^{111}In satumomab pentetide, 155

1H10, radiochemical purity and immunoreactivity, temperature effects, 126(ab)

Motion correction, cardiac SPECT, four different techniques, 122(ab)

Myocardial infarction, tracer uptake in, SPECT images, 252

Myocardial perfusion imaging

defects, ultra-high energy collimation effects, 122(ab)

first-pass studies

versus gated blood-pool studies, 134(ab)
 ^{99m}Tc sestamibi, syringes used for, 121(ab)

gated SPECT, cardiac function, 72
nuclear cardiology, 164

phantom, tracer uptake in myocardial infarction, 252
 simulated frame-loss artifacts in, single- and dual-headed systems, 248
^{99m}Tc sestamibi, arm positioning effects, 115(ab)
^{99m}Tc-tetrofosmin liver clearance, acute chest pain patients, 186
Myocardium. ^{99m}Tc-tetrofosmin count statistics, stress effects, 116(ab)

N

National Council on Radiation Protection and Measurements (NCRP), W. Roger Ney retires, 104
Needle stick injury, sensible approaches, nuclear medicine and pharmacy, 135(ab)
Neuropathy, peripheral, osseous metastases after ¹⁸⁶Re HEDP/⁸⁹Sr treatment, 131(ab)
Neuropsychology, cognition, PET activation, 17
NMTCB, *see* Nuclear Medicine Technology Certification Board
Nuclear cardiology
 anatomy and function of the heart, 4, 72, 164
 radioactive contamination incidents, reduction of, 133(ab)
Nuclear medicine
 new image procedures for technologists, 127(ab)
 patient education in the 21st century, 235
Nuclear Medicine Technology Certification Board (NMTCB)
 report from chair, 51, 101, 209, 284
 task analysis report 1997, 52
Nuclear medicine technology education, curriculum design, 278
Nuclear pharmacy, centralized, ¹³¹I, solution volume and storage time effects on dissolution, 274
Nuclear Regulatory Commission (NRC)
 radiation dosage, decisions and instructions, 124(ab)
 regulatory release criteria, ¹³¹I-labeled antibodies, 121(ab)

O

Ocular tumors, imaging, planar pinhole technique or SPECT, 119(ab)
Organ uptake ratios, static versus variable speed whole-body acquisition, 126(ab)
Osseous metastases, after ¹⁸⁶Re HEDP/⁸⁹Sr treatment, peripheral neuropathy in, 131(ab)
Osteoarthritis, bone scintigraphy in, 133(ab)
Oxygen-15, gas delivery system, PET imaging, 135(ab)

P

Parkinson's disease, ¹²³I β-CIT clinical evaluation, 114(ab)
Patient education, health care in the 21st century, 235
Pediatric patients
 ictal brain SPECT, technical protocol, 116(ab)
 renal scintigraphy, ^{99m}Tc MAG3, calculation of split function in, 116(ab)

Peer review process, 69(ed)
Peptides. ^{99m}Tc labeled, imaging carotid thrombi with, 117(ab)
Performance criteria, scintillation cameras, 9
Phosphorus-32, radionuclide therapy, bone malignancy, 80
Positron emission tomography (PET)
 activation, in neurological disorders, 17
 altropane as ligand, imaging of dopamine transporters, 113(ab)
FDG
 fully corrected whole-body studies, 118(ab)
 plasma time-activity curve and external TLD measurement, 131(ab)
 filtered backprojection, versus expectation-maximization methods, 134(ab)
 high-quality FDG studies, dual-headed gamma camera, 245
 quantitative, arterial sampling via indwelling ports for, 130(ab)
 radiopharmaceuticals in, 228
 whole-body FDG and off-site FDG, patient throughput for, 129(ab)
 World Wide Web, continuing education and internal communication, 130(ab)
¹¹C β-CFT, imaging of dopamine transporters, 135(ab)
¹⁸F-FDG, lung cancer, Medicare coverage, 63
¹⁵O gas delivery system testing, 135(ab)
Power spectrum, 2D, SPECT images assessed by textual analysis, 128(ab)
Preparation problems. ^{99m}Tc radiopharmaceuticals, 262
Professional practice, ACNP test to develop critical thinking, 38
Proficiency testing, ACNP test to develop critical thinking, 38
Prostate cancer
¹¹¹In capromab pentetide monoclonal antibody imaging, protocol for, 174
¹¹¹In ProstaScint[®] dual-isotope protocol for, 120(ab)
 screening, total prostate-specific antigen, 126(ab)
⁸⁹Sr therapy, 117(ab)
Prostate-specific antigen, free, screening of prostate cancer, 126(ab)

Q

Quality control
 dose calibrators, geometry parameter for, 127(ab)
 positron emitters, dual-head positron coincidence detection gamma camera, 127(ab)
 procedures
 radiochemical purity, miniaturized chromatography, 125(ab)
 radiochemical purity of ¹¹¹In SP, 125(ab)
 scintillation cameras, 9
 test, modified preparation of ^{99m}Tc-tetrofosmin, 269
¹⁸⁸Rh-labeled compounds, nuclear medicine laboratory, 118(ab)
^{99m}Tc preparation problems, 262
Quantitation. ¹²³I IPPA metabolic images, quantitative method for analysis, 133(ab)
 lung imaging, 26

R

Radiation, dosage, decisions and instructions, 124(ab)
Radiation safety
 labeling efficiency and stability, ^{99m}Tc MDP and sestamibi, 124(ab)
 needle-stick injuries, nuclear medicine and pharmacy, 135(ab)
 patient dies after therapy, 206
 radiopharmaceuticals in PET imaging, 228
 reduction of radioactive contamination incidents, 133(ab)
^{99m}Tc-DTPA contamination, in lung ventilation studies, 43
Radioactive cadaver, radiation safety, patient dies after therapy, 206
Radiochemical purity testing. ^{99m}Tc preparation problems, 262
Radioimmunoimaging. ^{99m}Tc-labeled anti-CEA monoclonal antibodies, clinical study, 123(ab)
Radioimmunotherapy
 high-dose, radiation safety, 128(ab)
¹³¹I-labeled antibodies, NRC regulatory release criteria, 121(ab)
Radioiodine, therapy, thyroid stunning, 134(ab)
Radionuclide angiography
 first-pass, ^{191m}Ir and ¹⁷⁸Ta comparison, 121(ab)
^{99m}Tc-HSA-D, occult intestinal bleeding imaged by, 30
Radionuclides, dual, SPECT, locus of infection or tumor, 119(ab)
Radionuclide therapy, bone malignancy, 80
Radionuclide tumor imaging
¹¹¹In capromab pentetide, prostate cancer, 174
¹¹¹In satumomab pentetide, FDA approved, 155
Radiopharmaceuticals
 for bone malignancy therapy, 80
 in PET imaging, 228
 radiochemical purity, quality control procedures, 125(ab)
 unit dose lead containers, single-use protective inserts, blood contamination and, 200
^{99m}Tc
 adsorption onto disposable plastic syringes, 196
 preparation problems, 262
^{99m}Tc MDP and sestamibi, labeling efficiency and stability, 124(ab)
Radiopharmacy. ^{99m}Tc preparation, dose from syringe procedures, 32
Red blood cell labeling
 evaluation of efficiency, chemotherapy in adults and children, 265
 substandard, cause of, 99(le)
 in vitro versus in vivo, gastrointestinal bleeding studies, 87
Red blood cells, heat-damaged, preparing for imaging in splenic infarct or trauma, 204
Renal ERPF, determination, ^{99m}Tc-MAG and single blood sampling, 23
Renography, diuretic, exclusion of renal obstruction, 117(ab)
Rhenium-186, radionuclide therapy, bone malignancy, 80
Rhenium-188, compounds labeled with, use and quality control, 118(ab)
Robotic synthesis, 6-F-18 FDOPA, 125(ab)

S

Samarium-153, radionuclide therapy, bone malignancy, 80

Scintigraphy

cardiac function, 72
labeled leukocyte, seronegative spondylarthropathies, 132(ab)
renal, ^{99m}Tc MAG3, calculation of split function in children, 116(ab)

Scintillation camera

measurement of blood activity, feasibility of, 125(ab)
quality control program, 9

Scintillation counter, well-type,

measurement of blood radioactivity, quantification of cerebral blood flow, 191

Scintimammography, prone, imaging breast cancer, 127(ab)

Sentinel nodes, localization

lymphoscintigraphy, breast cancer, 120(ab)
 ^{99m}Tc human serum albumin or sulfur colloid, breast cancer patients, 120(ab)

Single-photon emission computed tomography (SPECT)

brain
assessment of lesion detectability, 130(ab)
collimators and nuclides with a texture analysis, 128(ab)
octreotide, meningioma patients, 119(ab)
dopamine system, radioactive reference markers and, 114(ab)
FDG, epilepsy, tumor, progressive aphasia and stroke, 114(ab)

heart

four motion correction techniques, 122(ab)
inferior wall perfusion defects, 115(ab)
 ^{99m}Tc sestamibi, arm position effects, 116(ab)
ultra-high energy collimation effects, 122(ab)
 ^{125}I , brachytherapy seeds, 124(ab)
 ^{111}In and ^{67}Ga , uniform attenuation correction, 117(ab)
quantitative results, Chang algorithm, attenuation map effects, 178
reflection of tracer uptake, myocardial infarction, 252
simulated frame-loss artifacts in, 248
simultaneous dual radiotracer, locus of infection or tumor, 119(ab)
 ^{201}Tl , volume measurements by, 123(ab)

SNM/ACNP Government Relations Office

annual report, 1997, 59
update, 103, 223, 286

Society of Nuclear Medicine

annual meeting
Technologist Section program, 107
Toronto meeting highlights, 212
Commission on Health Care Policy, roadshow, 64
convention booths, 65
Education and Research Foundation, award winners, 65
Technologist Section, performance and responsibility guidelines, 45

Solution volume, storage time and, effects on in vitro dissolution, ^{131}I , 274

Spectral analysis, quantification of dynamic PET studies, 130(ab)

Spleen, imaging, preparing heat-damaged red cells for, in infarct or trauma, 204

Spondylarthropathies, seronegative, labeled leukocyte scintigraphy in, 132(ab)

Storage time, solution volume and, effects on in vitro dissolution, ^{131}I , 274

Stroke, acute, white blood cell kinetics after, 114(ab)

Strontium-89

radionuclide therapy, bone malignancy, 80
therapy, breast and prostate cancer, 117(ab)

Syringes

disposable plastic, adsorption of some ^{99m}Tc radiopharmaceuticals on, 196
procedures using, extremity exposure to ^{99m}Tc , 32

T

Technetium-99m

adsorption, onto disposable plastic syringes, 196
generator
elution time and eluate volume in, 118(ab)
fractionation elution performance, 130(ab)
preparation problems, 262
radiopharmaceutical preparation, dose from syringe procedures during, 32
red blood cell labeling, chemotherapy in adults and children, 265
 ^{201}Tl comparison, myocardial phantom in infarction, 252

Technetium-99m BICISATE, quantitative brain imaging, head injury patients, 113(ab)

Technetium-99m-DTPA, aerosol, contamination, lung ventilation studies, 43

Technetium-99m-HSA-D, radionuclide angiography, occult intestinal bleeding imaged by, 30

Technetium-99m-MAA, lung scan, for lung volume reduction surgery, 26

Technetium-99m-MAG3

renal scintigraphy, calculation of split function, children, 116(ab)
single blood sampling and, ERPF determination, 23

Technetium-99m MIBI, planar pinhole technique or SPECT, ocular tumors, 119(ab)

Technetium-99m-RBC, heat-damaged red cells, diagnosing splenic infarct or trauma, 204
radionuclide ventriculography, 265

Technetium-99m-sestamibi

first-pass doses, comparison of syringes used for, 121(ab)
SPECT, myocardial perfusion defects, 115(ab)

use in cardiac perfusion, 164

Technetium-99m-tetrofosmin

liver clearance of, acute chest pain patients, 186

modified preparation, rapid quality control test, 269
myocardial count statistics, stress effects, 116(ab)
radiochemical purity, fractionated kit, 128(ab)
use in cardiac perfusion, 164

Technologist, performance and responsibility guidelines for, 45

Technologist News, 59, 103, 212, 285

Temperature, effects on radiochemical purity and immunoreactivity, monoclonal antibody 1H10, 126(ab)

Thallium-201

gated SPECT, volume measurements by, collimator and total myocardial count effects, 123(ab)
use in cardiac perfusion, 164
 ^{99m}Tc comparison, myocardial phantom in infarction, 252

Thyroid cancer

dosimetry measurements in, 121(ab)
metastasis and, value of ^{123}I total-body scan in, 129(ab)
radiation safety, patient dies after therapy, 206

Thyroid disease, congenital, migrational anomalies, scintigraphy, 129(ab)

Thyroid gland, stunning, radioiodine therapy, 134(ab)

Tin-117m, radionuclide therapy, bone malignancy, 80

U

UltraTag[®] kit

heat-damaged red cells, splenic infarct or trauma, 204
substandard radiolabeling of red blood cells, 99(le)

Unit dose lead containers, single-use protective inserts, blood contamination and, 200

V

Ventilation, ^{133}Xe lung, after perfusion imaging with ^{99m}Tc , 131(ab)

Ventriculography, radionuclide cardiac function, 72

chemotherapy in adults and children, 265

Verification of Involvement in Continuing Education (VOICE), 59, 103, 219, 285

W

White blood cells, cerebral, kinetics, after acute stroke, 114(ab)

Wipe testing, gamma camera system for, 100(le)

Women's Health Information Kit, 65

Workforce Analysis Committee, manpower data survey, 208

World Wide Web, PET, continuing education and internal communication, 130(ab)

X

Xenon-133, dynamic SPECT, quantitative cerebral blood flow, 126(ab)

Xenon-133 gas, lung scan, for lung volume reduction surgery, 26